Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Health Communication to Influence COVID-19 Vaccination Intent and Message Propagation (CONVINCE)

16 février 2022 mis à jour par: Nicholas Hing Yee Liang, Clinical Research Centre, Malaysia

Effective Public Health Communication to Influence COVID-19 Vaccination Intent and Message Propagation: A Randomized Controlled Experiment

This is a randomised controlled experiment in the form of a web based survey study which randomly exposes participants to different forms of public health messages, after which participants will be assessed on their intent to take up the COVID-19 vaccine, recommend the vaccine, and also willingness to propagate the exposed message.

Aperçu de l'étude

Type d'étude

Interventionnel

Inscription (Réel)

5784

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

    • Selangor
      • Shah Alam, Selangor, Malaisie, 40170
        • Institute for Clinical Research, National Institutes of Health, Malaysia

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Oui

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  • Willing and able to give informed consent for participation in the trial
  • Malaysian nationality.
  • Can understand either the English or Malay language.
  • Aged 18 years or above

Exclusion Criteria:

  • Received at least one COVID-19 vaccination dose

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Autre
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Seul

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Descriptive Norm (70%)

Intervention in the form of a message likened to a social media post. Composed of 3 parts:

  1. Opening tag line highlighting the main concern that Malaysians have about the COVID-19 vaccine (safety and side effects)
  2. Message content describing that about 70% of Malaysians have expressed acceptance for the COVID-19 vaccine.
  3. Rally slogan: "It's safe and effective!"
Participants exposed to a health message and requested to read it completely. Subsequently requested to answer post intervention questions that form basis for outcome measures.
Expérimental: Descriptive Norm

Intervention in the form of a message likened to a social media post. Composed of 3 parts:

  1. Opening tag line highlighting the main concern that Malaysians have about the COVID-19 vaccine (safety and side effects)
  2. Message content describing that the COVID-19 vaccine has been widely tested including with the elderly and people with existing health conditions, while subsequently highlighting that the vaccine was already received by millions worldwide.
  3. Rally slogan: "It's safe and effective!"
Participants exposed to a health message and requested to read it completely. Subsequently requested to answer post intervention questions that form basis for outcome measures.
Expérimental: Healthcare worker (HCW) recommendation

Intervention in the form of a message likened to a social media post. Composed of 3 parts:

  1. Opening tag line highlighting the main concern that Malaysians have about the COVID-19 vaccine (safety and side effects)
  2. Message content highlights recommendation from Malaysian healthcare workers to get the vaccine, since majority of them has already received it, including the Malaysian Health Director General
  3. Rally slogan: "It's safe and effective!"
Participants exposed to a health message and requested to read it completely. Subsequently requested to answer post intervention questions that form basis for outcome measures.
Expérimental: Negative attribute framing

Intervention in the form of a message likened to a social media post. Composed of 3 parts:

  1. Opening tag line highlighting the main concern that Malaysians have about the COVID-19 vaccine (safety and side effects)
  2. Message content describing the rate of side effects occurring with COVID-19 vaccination in a negative frame.
  3. Rally slogan: "It's safe and effective!"
Participants exposed to a health message and requested to read it completely. Subsequently requested to answer post intervention questions that form basis for outcome measures.
Expérimental: Positive attribute framing

Intervention in the form of a message likened to a social media post. Composed of 3 parts:

  1. Opening tag line highlighting the main concern that Malaysians have about the COVID-19 vaccine (safety and side effects)
  2. Message content describing the rate of side effects occurring with COVID-19 vaccination in a positive frame.
  3. Rally slogan: "It's safe and effective!"
Participants exposed to a health message and requested to read it completely. Subsequently requested to answer post intervention questions that form basis for outcome measures.
Expérimental: Risky choice framing (Safety)

Intervention in the form of a message likened to a social media post. Composed of 3 parts:

  1. Opening tag line highlighting the main concern that Malaysians have about the COVID-19 vaccine (safety and side effects)
  2. Message content describing a risky choice frame which compares the death rates occurring with COVID-19 vaccination versus contracting the virus itself.
  3. Rally slogan: "It's safe and effective!"
Participants exposed to a health message and requested to read it completely. Subsequently requested to answer post intervention questions that form basis for outcome measures.
Expérimental: Risky choice framing (Side effects)

Intervention in the form of a message likened to a social media post. Composed of 3 parts:

  1. Opening tag line highlighting the main concern that Malaysians have about the COVID-19 vaccine (safety and side effects)
  2. Message content describing a risky choice frame that compares the incidence rates of blood clots occurring with COVID-19 vaccination versus contracting COVID-19.
  3. Rally slogan: "It's safe and effective!"
Participants exposed to a health message and requested to read it completely. Subsequently requested to answer post intervention questions that form basis for outcome measures.
Expérimental: Control message
Control message containing only rally slogan: "It's safe and effective!"
Participants exposed to a health message and requested to read it completely. Subsequently requested to answer post intervention questions that form basis for outcome measures.
Expérimental: Combination message: Descriptive Norm (70%) + Descriptive Norm
Participants received 2 messages which were exposed one at a time. Sequence of message appearing randomly rotated.
Participants exposed to a health message and requested to read it completely. Subsequently requested to answer post intervention questions that form basis for outcome measures.
Expérimental: Combination message: Descriptive Norm (70%) + HCW recommendation
Participants received 2 messages which were exposed one at a time. Sequence of message appearing randomly rotated.
Participants exposed to a health message and requested to read it completely. Subsequently requested to answer post intervention questions that form basis for outcome measures.
Expérimental: Combination message: Descriptive Norm (70%) + Negative attribute framing
Participants received 2 messages which were exposed one at a time. Sequence of message appearing randomly rotated.
Participants exposed to a health message and requested to read it completely. Subsequently requested to answer post intervention questions that form basis for outcome measures.
Expérimental: Combination message: Descriptive Norm (70%) + Positive attribute framing
Participants received 2 messages which were exposed one at a time. Sequence of message appearing randomly rotated.
Participants exposed to a health message and requested to read it completely. Subsequently requested to answer post intervention questions that form basis for outcome measures.
Expérimental: Combination message: Descriptive Norm (70%) + Risky choice framing (Safety)
Participants received 2 messages which were exposed one at a time. Sequence of message appearing randomly rotated.
Participants exposed to a health message and requested to read it completely. Subsequently requested to answer post intervention questions that form basis for outcome measures.
Expérimental: Combination message: Descriptive Norm (70%) + Risky choice framing (Side effects)
Participants received 2 messages which were exposed one at a time. Sequence of message appearing randomly rotated.
Participants exposed to a health message and requested to read it completely. Subsequently requested to answer post intervention questions that form basis for outcome measures.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Change in intent to accept the COVID-19 vaccine amongst the Malaysian adult population.
Délai: Immediately before and after message exposure during questionnaire administration.
Outcome measure was assessed using a questionnaire answered through a 4 point ordinal scale. Scale ranges from '"Definitely no", "Not sure, but probably no", "Not sure, but probably yes"to Definitely yes".
Immediately before and after message exposure during questionnaire administration.
Change in intent to recommend the COVID-19 vaccine to healthy adults.
Délai: Immediately before and after message exposure during questionnaire administration.
Outcome measure was assessed using a questionnaire answered through a 5 point ordinal scale. Scale ranges from "Strongly disagree", "Disagree", "Not sure", "Agree", and "Strongly agree".
Immediately before and after message exposure during questionnaire administration.
Change in intent to recommend the COVID-19 vaccine to elderly.
Délai: Immediately before and after message exposure during questionnaire administration.
Outcome measure was assessed using a questionnaire answered through a 5 point ordinal scale. Scale ranges from "Strongly disagree", "Disagree", "Not sure", "Agree", and "Strongly agree".
Immediately before and after message exposure during questionnaire administration.
Change in intent to recommend the COVID-19 vaccine to people with existing health conditions.
Délai: Immediately before and after message exposure during questionnaire administration.
Outcome measure was assessed using a questionnaire answered through a 5 point ordinal scale. Scale ranges from "Strongly disagree", "Disagree", "Not sure", "Agree", and "Strongly agree".
Immediately before and after message exposure during questionnaire administration.
Intent to share message on social media platform.
Délai: Immediately after message exposure during questionnaire administration.
Outcome measure was assessed using a questionnaire answered through a 5 point ordinal scale.Scale ranges from "Strongly disagree", "Disagree", "Not sure", "Agree", and "Strongly agree".
Immediately after message exposure during questionnaire administration.

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Moderators of vaccination intent.
Délai: Immediately after message exposure during questionnaire administration.
Outcome measure assessed using a series of questions answered through a 5 point ordinal scale. Scale ranges from "Strongly disagree", "Disagree", "Not sure", "Agree", and "Strongly agree".
Immediately after message exposure during questionnaire administration.
Reliability of various information sources about COVID-19.
Délai: Immediately after message exposure during questionnaire administration.
Outcome measure assessed using a questionnaire that list out various types of information sources and having participants to rate the reliability for each source using a 5 point ordinal scale. Scale ranges from "Strongly not reliable", "Not reliable, "Not sure", "Reliable", and "Strongly reliable".
Immediately after message exposure during questionnaire administration.

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

29 avril 2021

Achèvement primaire (Réel)

7 juin 2021

Achèvement de l'étude (Réel)

7 juin 2021

Dates d'inscription aux études

Première soumission

10 février 2022

Première soumission répondant aux critères de contrôle qualité

16 février 2022

Première publication (Réel)

17 février 2022

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

17 février 2022

Dernière mise à jour soumise répondant aux critères de contrôle qualité

16 février 2022

Dernière vérification

1 février 2022

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

NON

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

Essais cliniques sur Infections à coronavirus

Essais cliniques sur Health message exposure

3
S'abonner